A randomized, double-blind, dose-comparison study of weekly interferon β-1a in relapsing MS
暂无分享,去创建一个
L. Kappos | E. Radue | R. Hohlfeld | M. Clanet | H. Hartung | M. Kooijmans-Coutinho | E. Radue | R. Hohlfeld | E. Tsao | M. Sandberg‐wollheim | Hans-Peter Hartung | A. Sandrock | M. Sandberg-wollheim | E. C. Tsao
[1] D. Bever,et al. PRISMS-4: Long-term efficacy of interferon-β-1a in relapsing MS , 2001, Neurology.
[2] Richard A. C. Hughes,et al. PRISMS-4: Long-term efficacy of interferon-&bgr;-1a in relapsing MS , 2001, Neurology.
[3] A. Compston,et al. Double-blind randomized multicenter dose-comparison study of interferon-β-1a (AVONEX): rationale, design and baseline data , 2001, Multiple sclerosis.
[4] M. Clanet. Interferon-Beta in the Treatment of Multiple Sclerosis , 2001, Multiple sclerosis.
[5] J. Grafman,et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. , 2000, Annals of neurology.
[6] J. Grafman,et al. Neuropsychological effects of interferon β‐1a in relapsing multiple sclerosis , 2000 .
[7] C Confavreux,et al. Relapses and progression of disability in multiple sclerosis. , 2000, The New England journal of medicine.
[8] J H Simon,et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. , 2000, The New England journal of medicine.
[9] R. Rudick,et al. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS , 1999, Neurology.
[10] G. Ebers,et al. Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis , 1998, The Lancet.
[11] G. Barker,et al. Precision and reliability for measurement of change in MRI lesion volume in multiple sclerosis: a comparison of two computer assisted techniques , 1998, Journal of neurology, neurosurgery, and psychiatry.
[12] R. Herndon,et al. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis , 1998, Neurology.
[13] Jeanelle Sheeder,et al. Magnetic resonance studies of intramuscular interferon β–1a for relapsing multiple sclerosis , 1998 .
[14] J. Nogales-Gaete,et al. [Treatment of multiple sclerosis with interferons]. , 1996, Revista médica de Chile (Impresa).
[15] C. Granger,et al. Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis , 1996, Annals of neurology.
[16] J. Whitaker. Interferon-beta for the treatment of multiple sclerosis , 1995, Journal of Neuroimmunology.
[17] S. Hauser. Treatment of Multiple Sclerosis , 1994, Neurology.
[18] D. Li,et al. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.
[19] D. Paty,et al. Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis , 1993, Neurology.
[20] D. Silberberg,et al. New diagnostic criteria for multiple sclerosis: Guidelines for research protocols , 1983, Annals of neurology.
[21] L. Freedman,et al. Allocation of patients to treatment groups in a controlled clinical study. , 1978, British Journal of Cancer.
[22] P. Armitage,et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design. , 1976, British Journal of Cancer.
[23] D R Taves,et al. Minimization: A new method of assigning patients to treatment and control groups , 1974, Clinical pharmacology and therapeutics.
[24] Tau Fluvalinate,et al. The European Agency for the Evaluation of Medicinal Products , 1997 .
[25] G. Barker,et al. Quantification of MRI lesion load in multiple sclerosis: a comparison of three computer-assisted techniques. , 1996, Magnetic resonance imaging.